Rubius Therapeutics (NASDAQ:RUBY – Get Rating) and Vigil Neuroscience (NASDAQ:VIGL – Get Rating) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Rubius Therapeutics and Vigil Neuroscience, as provided by MarketBeat.com.
Get Rubius Therapeutics alerts:| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rubius Therapeutics | 0 | 1 | 0 | 0 | 2.00 |
| Vigil Neuroscience | 0 | 1 | 4 | 0 | 2.80 |
Rubius Therapeutics presently has a consensus target price of $8.00, suggesting a potential upside of 37,995.24%. Vigil Neuroscience has a consensus target price of $18.80, suggesting a potential upside of 88.19%. Given Rubius Therapeutics' higher probable upside, equities research analysts clearly believe Rubius Therapeutics is more favorable than Vigil Neuroscience.
Risk and Volatility
Rubius Therapeutics has a beta of 2.38, meaning that its stock price is 138% more volatile than the S&P 500. Comparatively, Vigil Neuroscience has a beta of 3.43, meaning that its stock price is 243% more volatile than the S&P 500.
Earnings & Valuation
This table compares Rubius Therapeutics and Vigil Neuroscience's revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rubius Therapeutics | N/A | N/A | -$179.67 million | ($2.38) | -0.01 |
| Vigil Neuroscience | N/A | N/A | -$68.31 million | ($2.19) | -4.56 |
Vigil Neuroscience is trading at a lower price-to-earnings ratio than Rubius Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
76.1% of Rubius Therapeutics shares are held by institutional investors. Comparatively, 88.9% of Vigil Neuroscience shares are held by institutional investors. 5.3% of Rubius Therapeutics shares are held by company insiders. Comparatively, 46.6% of Vigil Neuroscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Profitability
This table compares Rubius Therapeutics and Vigil Neuroscience's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rubius Therapeutics | N/A | -212.29% | -86.74% |
| Vigil Neuroscience | N/A | -38.38% | -36.59% |
Summary
Vigil Neuroscience beats Rubius Therapeutics on 9 of the 11 factors compared between the two stocks.
About Rubius Therapeutics
(Get Rating)
Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. It provides medicine for cancer, autoimmune diseases, hemophilia, infectious and metabolic diseases. The company was founded on April 26, 2013 and is headquartered in Foxboro, MA.
About Vigil Neuroscience
(Get Rating)
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts. Vigil Neuroscience, Inc. operates as a subsidiary of Amgen Inc.
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.